About Us
Meet Our Team
Management Team
Kerry Clem
CEO
Kerry Clem
Chief Executive Officer: Joined Solaxa in 2024 as CCO before being appointed CEO. He has over 25 years of leadership experience in the life sciences industry, with a strong record of driving organizational excellence and long-term value creation for innovative life science companies. Kerry’s experience spans corporate strategy, product development, business development, and full life-cycle management. Before Solaxa, he served as CCO at Acorda Therapeutics, where he led the commercial success of Ampyra®, the extended-release formulation of 4-AP for multiple sclerosis, a franchise that generated over $5B in sales during his tenure. His prior roles also include VP, Sales & Marketing at Solstice Neurosciences and VP, Sales at Allos Therapeutics, both start-up organizations.
Christian Walker
CDO & Founder
Mary Hogan
Chief Development Officer and Founder: Mr. Walker has over 20 years of entrepreneurial and senior management experience in the commercialization of nerve technologies. He completed his MBA at the Isenberg School of Management at the University of Massachusetts Amherst, a Master’s degree in Biomedical Engineering from the University of Massachusetts Medical School and a Master’s degree in Cell and Molecular Biology from the University of Texas at Austin in the lab whose technology and resulting IP would later become the basis for AxoGen’s lead product Avance.
Mark Noble
CSO & Co-Founder
Mary Hogan
Chief Scientific Officer and Co-Founder:Dr. Noble is a pioneering researcher in the fields of stem cell biology and a key opinion leader in the field of regenerative medicine. Current research efforts and collaborations are focused on developing pharmacological and cell-based approaches to treatment of spinal cord injury and development of novel treatments for peripheral nerve injury. He is an inventor on 15 filed or pending patents and is co-author of over 150 scientific publications. Dr. Noble was a member of the founding scientific advisory board of Acorda Therapeutics, Inc., the company that first commercialized branded 4-AP. Dr. Noble is also a member of the multi-billion-dollar California Institute of Regenerative Medicine’s (CIRM) Grants Working Group, the panel of independent scientific experts used to review promising regenerative research applications for funding. Dr. Noble received his Ph.D. from Stanford University. He is the Martha M. Freeman, MD Professor in Biomedical Genetics, and holds professorships in Neurology, Neurobiology and Anatomy at University of Rochester School of Medicine where he is Director of the University of Rochester Stem Cell and Regenerative Medicine Institute.
Pete Zaudtke
Head of BD
Peter Zaudtke
Head of Business Development: Peter has over 20 years of experience across all life sciences sectors, primarily in corporate development for startups and SMEs. He served as CFO in an international biotech startup launching an oncology supportive care business before exiting. He also served as SVP, Head of Europe, building out the international corporate and commercial infrastructure for a gyno-urologic medtech. Pete founded and has run a successful strategic advisory firm for 15 years, specializing in route-to-market strategic consulting and global execution. He has successfully raised funds across Seed, A, and B rounds for multiple companies, with a first exit targeted for early 2027.
Amy Chappell
Chief Medical Officer
Amy Chappell, MD, FAAN
Chief Medical Officer: Amy is a board-certified neurologist with over 25 years of broad strategic and operational experience across all phases of drug development at Eli Lilly. She has led innovative clinical programs in epilepsy, ALS, MS, migraine, chronic pain, Alzheimer’s, and Parkinson’s, and played a key role in multiple FDA approvals, including duloxetine for fibromyalgia, osteoarthritis, and chronic low back pain. Amy brings deep regulatory expertise, successful out-licensing and due diligence experience, and a strong global network of neurologists and advocacy leaders.
Foundation Partners
